Clinical trial
A Prospective, Single-Arm, Phase Ib/II Clinical Trial of Chidamide in Combination With Toripalimab and Anlotinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Failed at Least One Prior Line of Therapy
NCT07320963 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Arm, Phase Ib/II Clinical Trial of Chidamide in Combination With Toripalimab and Anlotinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Failed at Least One Prior Line of Therapy
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- March 31, 2026
- Completion date
- March 28, 2028
- Enrollment
- 52 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.